4147.TWO
TaiMed Biologics Inc. [4147.TWO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
4147.TWO Stock Summary
Top 10 Correlated ETFs
4147.TWO
Top 10 Correlated Stocks
4147.TWO
In the News
4147.TWO Financial details
Company Rating
Neutral
Market Cap
23.78B
Income
-198.34M
Revenue
491.78M
Book val./share
10
Cash/share
2.53
Dividend
-
Dividend %
-
Employees
79
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-142.8
Forward P/E
-
PEG
49.09
P/S
33.35
P/B
9.67
P/C
32.85
P/FCF
-358.82
Quick Ratio
2.26
Current Ratio
6.05
Debt / Equity
0.29
LT Debt / Equity
0.2
-
-
EPS (TTM)
-0.77
EPS next Y
-
EPS next Q
-
EPS this Y
-30.28%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-19.58%
Revenue last 5Y
-6.94%
Revenue Q/Q
0.42%
EPS Q/Q
904.37%
-
-
-
-
SMA20
-
SMA50
7.06%
SMA100
9.64%
Inst Own
-
Inst Trans
-
ROA
-4%
ROE
-7%
ROC
-0.04%
Gross Margin
43%
Oper. Margin
-24%
Profit Margin
-27%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
76.3-135.0
52W High
-38.44%
52W Low
+9.34%
RSI
37
Rel Volume
0.88
Avg Volume
2.34M
Volume
2.06M
Perf Week
-10.84%
Perf Month
-19.71%
Perf Quarter
0.12%
Perf Half Y
-1.07%
-
-
-
-
Beta
0.458
-
-
Volatility
4.03%, 4.29%
Prev Close
-4.26%
Price
83.1
Change
-5.35%
4147.TWO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.76 | 2.82 | 1.62 | 2.2 | 1.92 | |
| Net income per share | -2.26 | -0.73 | -1.87 | -1.09 | -0.76 | |
| Operating cash flow per share | -2.56 | -0.79 | -0.83 | -2.36 | -0.1 | |
| Free cash flow per share | -3.1 | -2.29 | -0.88 | -2.38 | -0.12 | |
| Cash per share | 4.98 | 4.7 | 3.75 | 2.52 | 2.53 | |
| Book value per share | 14.03 | 13.35 | 11.49 | 10.6 | 10 | |
| Tangible book value per share | 11.13 | 9.68 | 8.28 | 7.77 | 7.56 | |
| Share holders equity per share | 14.03 | 13.35 | 11.49 | 10.6 | 10 | |
| Interest debt per share | 0.13 | 2.24 | 2.25 | 3.03 | 2.99 | |
| Market cap | 25.34B | 21.52B | 18.07B | 18.1B | 21.01B | |
| Enterprise value | 25.02B | 21.52B | 18.09B | 18.59B | 21.51B | |
| P/E ratio | -43.76 | -114.83 | -37.77 | -64.79 | -107.85 | |
| Price to sales ratio | 35.97 | 29.78 | 43.7 | 32.15 | 42.72 | |
| POCF ratio | -38.67 | -106.56 | -85.53 | -29.91 | -820.67 | |
| PFCF ratio | -31.95 | -36.69 | -80.37 | -29.68 | -661.67 | |
| P/B Ratio | 7.07 | 6.3 | 6.14 | 6.67 | 8.19 | |
| PTB ratio | 7.07 | 6.3 | 6.14 | 6.67 | 8.19 | |
| EV to sales | 35.51 | 29.78 | 43.74 | 33.03 | 43.74 | |
| Enterprise value over EBITDA | -51.51 | -545.62 | -58.94 | -180.98 | -874.03 | |
| EV to operating cash flow | -38.18 | -106.55 | -85.6 | -30.72 | -840.2 | |
| EV to free cash flow | -31.55 | -36.69 | -80.44 | -30.48 | -677.41 | |
| Earnings yield | -0.02 | -0.01 | -0.03 | -0.02 | -0.01 | |
| Free cash flow yield | -0.03 | -0.03 | -0.01 | -0.03 | 0 | |
| Debt to equity | 0.01 | 0.17 | 0.19 | 0.28 | 0.29 | |
| Debt to assets | 0.01 | 0.11 | 0.12 | 0.19 | 0.19 | |
| Net debt to EBITDA | 0.66 | 0.07 | -0.05 | -4.79 | -20.31 | |
| Current ratio | 5.74 | 6.02 | 10.37 | 6.56 | 5.96 | |
| Interest coverage | -1.62K | -43.84 | -62.26 | -25.66 | -11.22 | |
| Income quality | 1.13 | 1.1 | 0.45 | 2.25 | 0.13 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.06 | 0.06 | 0.11 | 0.09 | 0.11 | |
| Research and developement to revenue | 0.82 | 0.55 | 1.11 | 0.59 | 0.6 | |
| Intangibles to total assets | 0.16 | 0.18 | 0.18 | 0.18 | 0.16 | |
| Capex to operating cash flow | 0.21 | 1.9 | 0.06 | 0.01 | 0.24 | |
| Capex to revenue | -0.2 | -0.53 | -0.03 | -0.01 | -0.01 | |
| Capex to depreciation | -1.49 | -2.75 | -0.09 | -0.03 | -0.04 | |
| Stock based compensation to revenue | 0.04 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Graham number | 26.73 | 14.83 | 21.98 | 16.13 | 13.08 | |
| ROIC | -0.16 | -0.05 | -0.13 | -0.08 | -0.05 | |
| Return on tangible assets | -0.15 | -0.04 | -0.13 | -0.08 | -0.06 | |
| Graham Net | 2.87 | 1 | 0.02 | 0.1 | 0.29 | |
| Working capital | 2.03B | 2.32B | 2.11B | 1.84B | 1.79B | |
| Tangible asset value | 2.85B | 2.48B | 2.12B | 1.99B | 1.94B | |
| Net current asset value | 1.31B | 997.52M | 665.72M | 778.81M | 823.56M | |
| Invested capital | 0.01 | 0.17 | 0.19 | 0.28 | 0.29 | |
| Average receivables | 166.11M | 246.16M | 220.63M | 134.93M | 130.38M | |
| Average payables | 143.02M | 71.17M | 64.37M | 61.34M | 6.79M | |
| Average inventory | 628.29M | 1.07B | 1.21B | 1.28B | 1.32B | |
| Days sales outstanding | 115.03 | 136.56 | 150.93 | 64.12 | 120.14 | |
| Days payables outstanding | 104.75 | 5.6 | 135.8 | 0.09 | 18.48 | |
| Days of inventory on hand | 673.88 | 1.15K | 1.29K | 1.45K | 1.73K | |
| Receivables turnover | 3.17 | 2.67 | 2.42 | 5.69 | 3.04 | |
| Payables turnover | 3.48 | 65.13 | 2.69 | 3.9K | 19.75 | |
| Inventory turnover | 0.54 | 0.32 | 0.28 | 0.25 | 0.21 | |
| ROE | -0.16 | -0.05 | -0.16 | -0.1 | -0.08 | |
| Capex per share | -0.54 | -1.5 | -0.05 | -0.02 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.27 | 0.28 | 0.41 | 0.61 | 0.62 | |
| Net income per share | -0.16 | -0.33 | -0.19 | -0.02 | -0.23 | |
| Operating cash flow per share | -0.01 | -0.33 | 0.06 | 0.06 | 0.11 | |
| Free cash flow per share | -0.01 | -0.33 | 0.05 | 0.05 | 0.1 | |
| Cash per share | 2.52 | 2.34 | 2.59 | 2.52 | 2.53 | |
| Book value per share | 10.6 | 10.32 | 10.32 | 10.3 | 10 | |
| Tangible book value per share | 7.77 | 7.59 | 7.69 | 7.77 | 7.56 | |
| Share holders equity per share | 10.6 | 10.32 | 10.32 | 10.3 | 10 | |
| Interest debt per share | 3 | 3 | 3 | 2.97 | 2.94 | |
| Market cap | 18.11B | 23.6B | 27.18B | 22.79B | 21.02B | |
| Enterprise value | 18.6B | 24.14B | 27.59B | 23.28B | 21.52B | |
| P/E ratio | -110.44 | -69.96 | -142.04 | -969.27 | -87.17 | |
| Price to sales ratio | 55.48 | 328.85 | 260.76 | 144.65 | 132.86 | |
| POCF ratio | -10.02K | -281.02 | 1.78K | 1.6K | 727.34 | |
| PFCF ratio | -6.4K | -280.26 | 2.21K | 1.7K | 785.53 | |
| P/B Ratio | 6.67 | 8.92 | 10.27 | 8.62 | 8.19 | |
| PTB ratio | 6.67 | 8.92 | 10.27 | 8.62 | 8.19 | |
| EV to sales | 56.99 | 336.37 | 264.66 | 147.77 | 136.02 | |
| Enterprise value over EBITDA | 4.08K | -632.84 | -5.24K | 636.16 | -1.21K | |
| EV to operating cash flow | -10.3K | -287.45 | 1.81K | 1.63K | 744.63 | |
| EV to free cash flow | -6.58K | -286.67 | 2.24K | 1.74K | 804.21 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.28 | 0.29 | 0.29 | 0.29 | 0.29 | |
| Debt to assets | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | |
| Net debt to EBITDA | 107.95 | -14.15 | -77.41 | 13.44 | -28.08 | |
| Current ratio | 6.56 | 6.84 | 6.34 | 6.05 | 5.96 | |
| Interest coverage | -10.74 | -21.88 | -11.75 | -0.56 | -7.06 | |
| Income quality | 0.05 | 1.04 | -0.32 | -2.42 | -0.48 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.04 | 0.21 | 0.12 | 0.09 | 0.09 | |
| Research and developement to revenue | 0.27 | 1.07 | 0.78 | 0.38 | 0.48 | |
| Intangibles to total assets | 0.18 | 0.17 | 0.17 | 0.16 | 0.16 | |
| Capex to operating cash flow | 0.57 | 0 | -0.19 | -0.06 | -0.07 | |
| Capex to revenue | 0 | 0 | -0.03 | -0.01 | -0.01 | |
| Capex to depreciation | -0.03 | -0.01 | -0.08 | -0.02 | -0.06 | |
| Stock based compensation to revenue | 0 | 0.04 | 0.03 | 0.02 | 0.01 | |
| Graham number | 6.18 | 8.74 | 6.58 | 2.3 | 7.27 | |
| ROIC | -0.01 | -0.02 | -0.01 | 0 | 0 | |
| Return on tangible assets | -0.01 | -0.03 | -0.01 | 0 | -0.02 | |
| Graham Net | 0.1 | 0.07 | 0.24 | 0.38 | 0.29 | |
| Working capital | 1.84B | 1.86B | 1.85B | 1.85B | 1.79B | |
| Tangible asset value | 1.99B | 1.94B | 1.97B | 1.99B | 1.94B | |
| Net current asset value | 778.81M | 783.74M | 826.05M | 858.99M | 823.56M | |
| Invested capital | 0.28 | 0.29 | 0.29 | 0.29 | 0.29 | |
| Average receivables | 146M | 134.9M | 146.29M | 151.54M | 171.63M | |
| Average payables | 660K | 178K | 4.16M | 16.55M | 19.28M | |
| Average inventory | 1.44B | 1.38B | 1.36B | 1.35B | 1.31B | |
| Days sales outstanding | 27.26 | 214.32 | 105.05 | 103.62 | 92.08 | |
| Days payables outstanding | 0.04 | 0.89 | 10.29 | 28.11 | 13.63 | |
| Days of inventory on hand | 635.49 | 4.6K | 1.73K | 1.51K | 1.28K | |
| Receivables turnover | 3.3 | 0.42 | 0.86 | 0.87 | 0.98 | |
| Payables turnover | 2.2K | 100.59 | 8.75 | 3.2 | 6.6 | |
| Inventory turnover | 0.14 | 0.02 | 0.05 | 0.06 | 0.07 | |
| ROE | -0.02 | -0.03 | -0.02 | 0 | -0.02 | |
| Capex per share | 0 | 0 | -0.01 | 0 | -0.01 |
4147.TWO Frequently Asked Questions
What is TaiMed Biologics Inc. stock symbol ?
TaiMed Biologics Inc. is a TW stock and trading under the symbol 4147.TWO
What is TaiMed Biologics Inc. stock quote today ?
TaiMed Biologics Inc. stock price is $83.1 today.
Is TaiMed Biologics Inc. stock public?
Yes, TaiMed Biologics Inc. is a publicly traded company.
Company Profile
- Volume Average 2.34M
- Market Capitalization 23.78B
- Employee 79
- CEO Mr. Chin-Ming Chang Ph.D.
- Headquarters Taipei,TW
- IPO Date 2012-06-20
-
Website
https://www.taimedbiologics.com 
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.
